|Title:||CPAP versus HFO therapy for severe COVID-19 ARDS|
|Author(s):||Walsh S, Curran E, Counihan I, and Hassan T|
|Institution:||Our Lady Of Lourdes Hospital, Drogheda, Co. Louth|
|Poster:||Click to view poster|
|Abstract:||The role of non-invasive respiratory support for viral induced acute respiratory distress syndrome has been unclear. |
This is an observational study conducted at Our Lady of Lourdes Hospital with Continuous Positive Airway Pressure (CPAP) and High Flow oxygen (HFO) commenced on individuals with confirmed Covid-19 pneumonia with PFR <200 despite conventional oxygen therapy. Statistical analysis was performed using the Kaplan Meier analysis to determine time to removal CPAP or HFO.
From 16th March 2020 to 30th April 2021, 796 laboratory-confirmed Covid-19 pneumonias were treated in OLOL. Three hundred and one patients with acute hypoxic respiratory failure that failed to achieve target SaO2 and pO2 with PFR 172 ± 25 (mean± SD), received CPAP during inpatient hospital stay (197 males and 104 females) with age of 61 ± 17 (mean± SD). PFR at 24 hours and Day 3 were higher with the CPAP group compared to HFO (p=0.03). The median number of organ support-free days was 5.7 days and 7.2 days in the CPAP and HFO group respectively
This study supports the use of CPAP over HFNO in the management of COVID-19 ARDS.